Literature DB >> 10027005

Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement.

H M Rabes1, S Klugbauer.   

Abstract

Epidemiological studies have revealed a connection between thyroid carcinogenesis and a history of radiation. The molecular mechanisms involved are not well understood. It has been claimed that RAS, p53 or GSP mutations and RET or TRK rearrangements might play a role in adult thyroid tumors. In childhood, the thyroid gland is particularly sensitive to ionizing radiation. The reactor accident in Chernobyl provided a unique chance to study molecular genetic aberrations in a cohort of children who developed papillary thyroid carcinomas after a short latency time after exposure to high doses of radioactive iodine isotopes. According to the concepts of molecular genetic epidemiology, exposure to a specific type of irradiation might result in a typical molecular lesion. Childhood papillary thyroid tumors after Chernobyl exhibit a high prevalence of RET rearrangement as almost the only molecular alteration. The majority showed RET/PTC3 (i.e., ELE/RET rearrangements), including several subtypes. Less frequently, RET/PTC1 (i.e., H4/RET rearrangements), and a novel type (RET/PTC5, i.e., RFG5/RET) were observed. Proof of reciprocal transcripts suggests that a balanced intrachromosomal inversion leads to this rearrangement. Breakpoint analyses revealed short homologous nucleotide stretches at the fusion points. In all types of rearrangement, the RET tyrosine kinase domain becomes controlled by 5' fused regulatory sequences of ubiquitously expressed genes that display coiled-coil regions with dimerization potential. Oncogenic activation of RET is apparently due to ligand-independent constitutive ectopic RET tyrosine kinase activity. The analysis of this cohort of children with radiation-induced thyroid tumors after Chernobyl provides insights into typical molecular aberrations in relation to a specific mode of environmental exposure and may serve as a paradigm for molecular genetic epidemiology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10027005     DOI: 10.1007/978-3-642-46870-4_16

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  6 in total

1.  Mechanistic basis for nonlinear dose-response relationships for low-dose radiation-induced stochastic effects.

Authors:  Bobby R Scott; Dale M Walker; Yohannes Tesfaigzi; Helmut Schöllnberger; Vernon Walker
Journal:  Nonlinearity Biol Toxicol Med       Date:  2003-01

2.  Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein.

Authors:  Josephine H F Wixted; Jay L Rothstein; Laurence C Eisenlohr
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

3.  Oncogenic rearrangements driving ionizing radiation-associated human cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

4.  Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy.

Authors:  Mary E. Barcus; Celeste N. Powers
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

5.  Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.

Authors:  Mi-Sook Lee; Ryong Nam Kim; Hoseok I; Doo-Yi Oh; Ji-Young Song; Ka-Won Noh; Yu-Jin Kim; Jung Wook Yang; Maruja E Lira; Chang Hun Lee; Min Ki Lee; Yeoung Dae Kim; Mao Mao; Joungho Han; Jhingook Kim; Yoon-La Choi
Journal:  Oncotarget       Date:  2016-06-14

Review 6.  Influencers on Thyroid Cancer Onset: Molecular Genetic Basis.

Authors:  Berta Luzón-Toro; Raquel María Fernández; Leticia Villalba-Benito; Ana Torroglosa; Guillermo Antiñolo; Salud Borrego
Journal:  Genes (Basel)       Date:  2019-11-08       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.